Stocks to watch: HDFC Bank, Sun Pharma, Vedanta, Nestle India, IDFC First Bank, KPI Green GIFT Nifty indicated that Indian equity indices BSE Sensex and NSE Nifty 50 may see a negative opening on Tuesday. Here’s a look at the key stocks to watch in trade. Stocks in Focus: GIFT Nifty traded slightly down by 13.50 points or 0.06% at 21,470.50, indicating a lacklustre opening for domestic indices NSE Nifty 50 and BSE Sensex on Tuesday. Previously, on Monday, the NSE Nifty 50 dropped 38 points or 0.18% to settle at 21,418.65, while the BSE Sensex ended lower by 168.66 points or 0.24% to 71,315.09. HDFC Bank raises a substantial Rs 7,425 crore through its inaugural 10-year infrastructure bond issue, securing funds at a 7.71% coupon rate. Sun Pharmaceutical Industries acquires a 16.7% stake in Massachusetts-based Lyndra Therapeutics for $30 million, expanding its global presence. Vedanta board approves a second interim dividend of Rs 11 per share, totaling Rs 4,089 crores; record date set for December 27. Nestle India sets a record date of January 5 for a 1:10 stock split, determining shareholders’ entitlement post-approval on October 19. Devyani International ventures into the Thailand market with the acquisition of 274 KFC outlets for Rs 1,066.10 crore; additionally invests Rs 340 crore in its Dubai-based global arm. IDFC First Bank receives regulatory approval from the RBI for the merger of IDFC and IDFC Financial Holding Co. with itself. India Glycols secures a major order from oil marketing and oil companies for the supply of 16.55 liters of ethanol, valued at Rs 1,164 crore, under the Ethanol Blended Petrol Programme. KPI Green initiates a Qualified Institutional Placement (QIP) aiming to raise up to Rs 300 crore, setting the floor price at Rs 1,245 per share, reflecting a 9.64% discount to the previous day’s closing. National Company Law Tribunal dismisses Olectra Greentech’s petition against MLR Motors for the recovery of Rs 10 crores. Biocon Biologics, a unit of Biocon, successfully completes the transition of the acquired biosimilars business across 120 countries in advanced and emerging markets.